Menarini Korea Limited, a wholly owned subsidiary of Italy’s Menarini Group, has struck a deal with UK R&D specialist Futura Medical plc for the exclusive rights to commercialize the latter’s topical, gel-based erectile dysfunction treatment MED3000 in South Korea.
Futura Strikes Deal With Menarini To Commercialize MED3000 ED Gel In South Korea
South Korean erectile dysfunction sufferers may soon be able to acess Futura Medical's drug-free MED3000 treatment thanks to a deal with Menarini Korea Limited, a wholly owned subsidiary of Italy’s Menarini Group, for exclusive commercialization rights in the country.